Trials / Completed
CompletedNCT03741972
Metabolic and Hemodynamic Effects of the Inhibitors of Type 2 Sodium Glucose Co-transporters (ISGLT2) in Diabetic Patients With Heart Failure
Metabolic and Hemodynamic Effects of the Inhibitors of Type 2 Sodium Glucose Co-transporters (ISGLT2) in Diabetic Patients With Heart Failure. GLUCOSUR-IC Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (actual)
- Sponsor
- Germans Trias i Pujol Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Inhibitors of the type 2 sodium-glucose co-transporter (iSGLT2) may improve the metabolic and hemodynamic profile in patients with DM2 and heart failure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | iSGTL2 | Treatment with empaglifozine 10 mg/day (may be also dapaglifozine 10mg/day depending on clinical trial results) |
Timeline
- Start date
- 2018-12-21
- Primary completion
- 2022-04-04
- Completion
- 2022-04-04
- First posted
- 2018-11-15
- Last updated
- 2022-10-14
Locations
1 site across 1 country: Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03741972. Inclusion in this directory is not an endorsement.